BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37089022)

  • 21. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
    Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
    World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients.
    Li X; Yi Y; Wu T; Chen N; Gu X; Xiang L; Jiang Z; Li J; Jin H
    Front Cell Infect Microbiol; 2023; 13():1170748. PubMed ID: 37260707
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
    Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
    Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
    Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma.
    Zhu HT; Liu RB; Liang YY; Hasan AME; Wang HY; Shao Q; Zhang ZC; Wang J; He CY; Wang F; Shao JY
    Liver Int; 2017 Jun; 37(6):888-896. PubMed ID: 28061012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota changes and its potential relations with thyroid carcinoma.
    Yu X; Jiang W; Kosik RO; Song Y; Luo Q; Qiao T; Tong J; Liu S; Deng C; Qin S; Lv Z; Li D
    J Adv Res; 2022 Jan; 35():61-70. PubMed ID: 35003794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion.
    Zhang N; Wang Z; Lv J; Zhang S; Liu Y; Liu T; Li W; Gong L; Zhang X; El-Omar EM; Lu W
    Front Med (Lausanne); 2022; 9():836369. PubMed ID: 35372388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
    Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
    Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
    Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
    Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
    Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma.
    Zhang T; Zhang S; Jin C; Lin Z; Deng T; Xie X; Deng L; Li X; Ma J; Ding X; Liu Y; Shan Y; Yu Z; Wang Y; Chen G; Li J
    Front Cell Infect Microbiol; 2021; 11():751795. PubMed ID: 34888258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.
    Rao BC; Lou JM; Wang WJ; Li A; Cui GY; Yu ZJ; Ren ZG
    Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):109-115. PubMed ID: 32037278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
    Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL
    PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of gut microbiota predictive potential associated with phenotypic characteristics to identify multifactorial diseases.
    Fonseca DC; Marques Gomes da Rocha I; Depieri Balmant B; Callado L; Aguiar Prudêncio AP; Tepedino Martins Alves J; Torrinhas RS; da Rocha Fernandes G; Linetzky Waitzberg D
    Gut Microbes; 2024; 16(1):2297815. PubMed ID: 38235595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.